MarilynAngelaMcLaughlinMD
Hematology • York, MEMyeloproliferative Disorder Hematology-Oncology
Physician
Dr. McLaughlin is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
15 Hospital Drive
York, ME 03909Phone+1 207-351-3777Fax+1 207-351-3788
Education & Training
Westchester Medical CenterFellowship, Hematology and Medical Oncology, 1996 - 1999- Westchester Medical CenterResidency, Internal Medicine, 1993 - 1996
Rutgers New Jersey Medical SchoolClass of 1993
Certifications & Licensure
ME State Medical License 2014 - 2026
NY State Medical License 1999 - 2025
NH State Medical License 2024 - 2024- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer Start of enrollment: 2017 Jan 18
- A Study of Abemaciclib (LY2835219) Plus Hormone Therapy in Participants With Early Breast Cancer Start of enrollment: 2021 May 10
- The National Myelodysplastic Syndromes (MDS) Study Start of enrollment: 2016 Jun 13
Roles: Principal Investigator, Contact
Publications & Presentations
PubMed
- 106 citationsTargeting protein disulfide isomerase with the flavonoid isoquercetin to improve hypercoagulability in advanced cancerJeffrey I. Zwicker, Benjamin L. Schlechter, Jack D. Stopa, Howard A. Liebman, Anita Aggarwal
JCI Insight. 2019-02-21
Press Mentions
York Hospital CEO Dr. Patrick Taylor Meets with Local LeadersMay 11th, 2021- York Hospital Receives Zero COVID Shots This Week for Phase 1b RecipientsJanuary 26th, 2021
Professional Memberships
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
